SonoVue

Phase 3Small molecule

BBracco Diagnostics, Inc

SonoVue is one of 180 small molecule programs targeting Stroke. It is currently in Phase 3.

Indications

Total Trials

Active Trials

179

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

Portal HypertensionActive, not recruiting

Pancreatic AdenocarcinomaActive, not recruiting

Breast CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Prostate CancerActive, not recruiting

StrokePhase 3

Active, not recruiting

Portal HypertensionPreclinical

Active, not recruiting

Pancreatic AdenocarcinomaPreclinical

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

Colorectal CancerPhase 1/Phase 2

Active, not recruiting

Prostate CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

SonoVue

BBracco Diagnostics, Inc

Phase 3

1 2

Tykerb

GSK

Preclinical

80 3

Avastin

Prolia

14 5

Gemzar

GGynecologic Oncology Group

Preclinical

22 6

Megace

Bristol-Myers Squibb

Preclinical

4 7

Voltaren

Novartis

Preclinical

1 8

Blenoxane

Bristol-Myers Squibb

Preclinical

1 9

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 10

Spravato

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Recruiting

Intravenous

NCT07113808

Q4 2026

N/ANot yet recruiting

Portal Hypertension

NCT07365709

Q2 2029

Phase 3Recruiting

Ultrasound

NCT06497959

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

Quantification of Contrast Enhanced Ultrasound (CEUS) in the Detection of Prostate Cancer

Terminated·—·N/A·NCT01481441·208 enrolled

Multiparametric Ultrasound Imaging in Prostate Cancer

Unknown status·—·N/A·NCT03101176·200 enrolled

Ultrasound2 trials

SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization

Completed·BBracco Diagnostics, Inc·Phase 3·NCT00829413·353 enrolled

Study of Placental Vascularization Using Contrast Ultrasound

Recruiting·—·Phase 3·NCT06497959·30 enrolled

Portal Hypertension1 trial

Liver Cirrhosis Complicated by Clinically Significant Portal Hypertension

Not yet recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·N/A·NCT07365709·107 enrolled

Breast Cancer1 trial

KVUS at Neoadjuvant CTx of Breast Cancer

Unknown status·RRWTH Aachen University·Phase 3·NCT03385200·60 enrolled

Pancreatic Adenocarcinoma1 trial

Contrast-harmonic Endoscopic Ultrasound (CH-EUS) for the Diagnosis of Pancreatic Adenocarcinoma

Completed·SSociété Française d'Endoscopie Digestive·N/A·NCT01765036·100 enrolled

7 more indications

Efficacy and Safety1 trial

An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound Imaging

Completed·GGE Healthcare·Phase 3·NCT03335566·424 enrolled

Completed·SSt. Olavs Hospital·Phase 1/2·NCT03477019·17 enrolled

Stroke1 trial

Contrast Enhanced Sonothrombolysis and Sonolysis in Stroke - a Swedish Study (CE-5S)

Terminated·UUmeå University·Phase 3·NCT03290053·1 enrolled

Pilot Study1 trial

A Pilot Study Evaluation of the Efficacy of SonoVue to Detect and Characterise Breast Lesions

Completed·UUniversity Hospital, Tours·N/A·NCT00243698·59 enrolled

Hemodynamic1 trial

Safety of SonoVue on Pulmonary Hemodynamics

Completed·BBracco Diagnostics, Inc·Phase 2·NCT01306292·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for SonoVue. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SonoVue compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SonoVue. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bracco Diagnostics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBracco Diagnostics, Inc

SonoVue

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2029

Trials by Indication[1]

Prostate Cancer2 trials

Ultrasound2 trials

Portal Hypertension1 trial

Breast Cancer1 trial

Pancreatic Adenocarcinoma1 trial

Efficacy and Safety1 trial

Echocardiography1 trial

Intravenous1 trial

Colorectal Cancer1 trial

Stroke1 trial

Pilot Study1 trial

Hemodynamic1 trial

References

Drug Info

Quick Facts

Related News